AIM ImmunoTech Announces Clinical Trial Agreement for a Phase 2a Human Challenge Trial of Ampligen as a Potential Intranasal Prophylaxis Against Respiratory Viruses
The governing ethics committee and regulatory agency have met on the study protocol and plan to issue their response in...